Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy

被引:0
作者
Jingkai Liu
Qiaofei Liu
Xiang Zhang
Ming Cui
Tong Li
Yalu Zhang
Quan Liao
机构
[1] Chinese Academy of Medical Sciences,Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College
来源
Cancer Cell International | / 21卷
关键词
Pancreatic cancer; Heterogeneity; Immune cell; Immune checkpoints; Immunotherapy; Transglutaminase 2;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 337 条
[21]  
Collisson EA(2014)Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity PLoS ONE 9 e88309-51
[22]  
Bailey P(2004)Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds PLoS Biol 2 e7-326
[23]  
Chang DK(2008)Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer Breast Cancer Res Treat 116 69-555
[24]  
Biankin AV(2018)Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations Oncogene 37 4639-12
[25]  
Thorsson V(2020)Mechanisms of T-cell exhaustion in pancreatic cancer Cancers 12 2274-34
[26]  
Gibbs DL(1838)Tissue-specific roles of NKT cells in tumor immunity Front Immunol 2018 9-1210
[27]  
Brown SD(2017)Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice Immunology 152 36-426
[28]  
Wolf D(2018)A paradigm shift in cancer immunotherapy: from enhancement to normalization Cell 175 313-895
[29]  
Bortone DS(2020)B cells and tertiary lymphoid structures promote immunotherapy response Nature 577 549-119
[30]  
Ou Yang T-H(2019)Combination of CTLA-4 and PD-1 blockers for treatment of cancer J Exp Clin Cancer Res 38 1-2194